Almost Half of European and US Pharmaceuticals Companies Struggle to Use Data Insight

John E. Kaye
- Published
- Home, Technology

Inability to generate and use insights undermines competitiveness at 48% of drug companies surveyed
Nearly half of pharmaceutical companies (48%) admit their competitiveness is suffering because they cannot extract or use insights from data they already have within their business. An equal percentage (48%) admit they do not use their own data for business decisions as well as they could.
The findings are from research among 300 senior decision-makers within the pharmaceutical industry in the UK, US, Germany, France, Spain and Sweden, conducted by Aspen Technology, a global leader in asset optimisation software.
The research also reveals how poor digital capabilities hit business performance. Almost half (49%) say their companies struggle to use data effectively to improve time to market.
“This should sound an alarm bell within the pharmaceutical industry,” said David Leitham, Senior Vice President and General Manager Pharma, AspenTech. “Leading organisations stand out for their ability to use data effectively across all aspects of drug manufacture. Data-driven organisations are faster to innovate and respond to opportunities or threats at speed.”
The research also found a widespread lack of predictive capabilities within the industry. Almost half (49%) of respondents say their companies are not good enough at predicting demand for a product and adjusting output to match it. And almost as many (48%) rate their organisation as either poor or ineffective at using data to predict and resolve supply shortages.
Companies that have a more advanced digital culture use data effectively across all aspects of drug manufacture. More than three-quarters (78%) of such “digital culture leaders” in the research describe themselves as effective at using data to predict product demand and to forecast and resolve supply shortages.
“Pharma manufacturers have traditionally been moving slowly and incrementally towards ‘Pharma 4.0’,” said Leitham. “For more than half of all organisations this needs to accelerate if they are to avoid falling further behind.”
Further information
RECENT ARTICLES
-
New IBM–NASA AI aims to forecast solar flares before they knock out satellites or endanger astronauts
-
AI is powering the most convincing scams you've ever seen
-
British firm Skyral to help Mongolia tackle pollution with AI traffic modelling
-
The nuclear medicine breakthrough transforming cancer care
-
Second to none: the watchmaker who redefined time for women
-
How AI agents are supercharging cybercrime
-
The CEO making culture the driving force for innovation
-
Penelope J. Corfield on the secret gestures that shape society
-
In Africa, hepatitis B is a silent killer. And a $1 test could stop it
-
'Our real rivals are TikTok and Netflix’ – iGaming firm Soft2Bet sets out strategy for global expansion
-
AI agents are just the start. Here’s what comes next
-
Why cybersecurity deserves a place in the political spotlight
-
Outpacing cyber threats, winning the race
-
Who is really cutting emissions? These satellites will tell us
-
New Science Matters supplement out now — Europe’s boldest ideas in one place
-
New app reveals hidden health risks in everyday foods
-
Alzheimer’s vaccine enters human trials aiming to stop disease before symptoms begin
-
US researchers develop storm-resistant drone to improve extreme weather forecasting
-
Robot folds 800 napkins in 24 hours as Dyna Robotics launches first commercial-ready embodied AI
-
New breast cancer radiotherapy technology launches in Europe
-
Blockchain boom could create over 1 million jobs by 2030, new report claims
-
Why modern computer games aren’t a patch on the classics
-
Watch: Robotic bellboys checking in to a hotel near you soon
-
Soft2Bet reflects on eight years of leadership and philanthropy in new film featuring CEO Uri Poliavich
-
Late Star Trek creator’s family donates $1M to heart disease research